Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,178,200.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 10,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $117.82, for a total transaction of $1,178,200.00. Following the completion of the sale, the chief executive officer now owns 10,140 shares in the company, valued at $1,194,694.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of United Therapeutics stock opened at $118.36 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.46 and a current ratio of 8.91. The firm’s 50-day simple moving average is $116.83 and its 200-day simple moving average is $100.56. United Therapeutics Co. has a twelve month low of $74.31 and a twelve month high of $127.31. The firm has a market cap of $5.14 billion, a P/E ratio of 9.87 and a beta of 0.87.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.69. The business had revenue of $356.30 million for the quarter, compared to analyst estimates of $343.68 million. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. The firm’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the business earned $3.58 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 9.96 earnings per share for the current fiscal year.

Several analysts have issued reports on the stock. Wedbush restated a “buy” rating and issued a $243.00 price target on shares of United Therapeutics in a research report on Wednesday. Jefferies Financial Group upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from $115.00 to $123.00 in a research report on Tuesday, March 10th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research report on Sunday, May 3rd. Credit Suisse Group restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, April 30th. Finally, Cowen restated a “buy” rating and issued a $145.00 price target on shares of United Therapeutics in a research report on Friday, June 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. United Therapeutics currently has a consensus rating of “Hold” and an average price target of $127.89.

A number of large investors have recently added to or reduced their stakes in the business. State Street Corp boosted its position in United Therapeutics by 1.1% in the first quarter. State Street Corp now owns 1,916,532 shares of the biotechnology company’s stock valued at $181,735,000 after buying an additional 21,707 shares in the last quarter. New Mexico Educational Retirement Board boosted its position in United Therapeutics by 38.2% in the first quarter. New Mexico Educational Retirement Board now owns 10,500 shares of the biotechnology company’s stock valued at $996,000 after buying an additional 2,900 shares in the last quarter. Optimal Asset Management Inc. boosted its position in United Therapeutics by 23.9% in the first quarter. Optimal Asset Management Inc. now owns 9,803 shares of the biotechnology company’s stock valued at $930,000 after buying an additional 1,892 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in United Therapeutics by 2.1% in the first quarter. The Manufacturers Life Insurance Company now owns 62,855 shares of the biotechnology company’s stock valued at $5,960,000 after buying an additional 1,271 shares in the last quarter. Finally, HighTower Advisors LLC boosted its position in United Therapeutics by 4.2% in the first quarter. HighTower Advisors LLC now owns 6,499 shares of the biotechnology company’s stock valued at $617,000 after buying an additional 263 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

See Also: Hang Seng Index (HSI)

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.